Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
MicroRNA
49%
Apoptosis
47%
Ovarian Cancer
46%
Tumor Necrosis Factor-α
42%
Tumor
42%
In Cancer
39%
Apoptosis Induction
35%
Nuclear factor-B
35%
NF-B
34%
Chronic Lymphocytic Leukemia
30%
Cancer Cells
29%
Tumor Cells
28%
Breast Cancer
27%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
26%
Phosphorylation
25%
Cytotoxicity
23%
Curcumin
23%
Monoclonal Antibody
20%
Small Interfering RNA (siRNA)
19%
Antitumor Activity
19%
Overexpression
18%
Ovarian Cancer Cells
18%
Fludarabine
18%
Tumor Growth
17%
Breast Cancer Cells
16%
Cell Proliferation
16%
Gene Products
15%
Long Non-coding RNA (LncRNA)
15%
Human Epidermal Growth Factor Receptor 2 (HER2)
15%
Acute Myeloid Leukemia
15%
Gene Expression
15%
Recombinant
15%
Doxorubicin
15%
Autophagy
14%
Metabolism
14%
Phosphoinositide 3-kinase (PI3K)
14%
Cisplatin
13%
Topoisomerase II
13%
Pharmacokinetics
13%
Transcription Factor
13%
Cell Growth
13%
B-cell Lymphoma 2 (Bcl-2)
13%
Non-coding RNA (ncRNA)
12%
Angiogenesis
12%
Overall Survival
12%
Leukemia
12%
Phase I Study
12%
Growth Inhibition
12%
Clinical Trials
12%
Signal Transducer
12%
Signaling Pathway
11%
Gemcitabine
11%
Nuclear factor-κB
11%
Interferon-α (IFN-α)
11%
Phase I Trial
11%
Tumorigenesis
11%
Activator of Transcription 3
11%
Cancer Treatment
11%
Cancer Therapy
10%
Carbohydrate Antigen 125 (CA125)
10%
Pancreatic Cancer
10%
Chemotherapy
10%
Cell Death
10%
Epithelial Ovarian Cancer
10%
Human Cancer
10%
Tumor Necrosis Factor Receptor 1 (TNFR1)
10%
Chronic Lymphocytic Leukemia Cells
10%
Metastasis
10%
Cyclin D1 (CCND1)
10%
Growth Factors
10%
Inflammation
10%
Anthracyclines
10%
Hypoxia-inducible factor-1α (HIF-1α)
10%
Triphosphate
10%
Epidermal Growth Factor
9%
Ara-C
9%
Liposomes
9%
Human Tumors
9%
Liposomal
9%
Cell Survival
9%
Activator protein-1 (AP-1)
9%
Tissue Transglutaminase
9%
DNA Damage
8%
Cyclooxygenase-2
8%
Colorectal Cancer
8%
Vascular Endothelial Growth Factor
8%
Liver
8%
DNA Synthesis
8%
Therapeutic Target
8%
Drug Resistance
8%
Osteoclastogenesis
8%
Nuclear Transcription Factor
8%
Cancer Patients
8%
Paclitaxel
8%
Nucleoside Analogues
8%
T Cells
8%
Mitogen-activated Protein Kinase
8%
Targeted Therapy
8%
Tumor Suppressor Gene
8%
Clinical Outcomes
8%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
73%
microRNA
33%
Ovary Cancer
33%
Tumor Necrosis Factor
32%
Alternative Complement Pathway C3 C5 Convertase
32%
Breast Cancer
31%
Cytotoxicity
30%
Nuclear Factor
30%
Phosphotransferase
28%
Chronic Lymphatic Leukemia
26%
Diseases
26%
Epidermal Growth Factor Receptor
25%
Receptor
25%
Curcumin
23%
Leukemia
23%
Pharmacokinetic
22%
Anticarcinogen
22%
Chemotherapy Regimen
20%
Antitumor Activity
19%
Doxorubicin
19%
Rat
18%
Protein Kinase B
18%
Monoclonal Antibody
17%
Tumor Growth
16%
Liposome
16%
Biological Marker
16%
Transcription Factor
16%
Clinical Trial
16%
Fludarabine
15%
Cisplatin
15%
Carcinogenesis
15%
Small Interfering RNA
14%
Acute Myeloid Leukemia
14%
Inflammation
13%
Pancreas Cancer
12%
Platinum
12%
Enzyme
12%
Drug Resistance
11%
Ovary Carcinoma
11%
Cytarabine
11%
Anthracycline
11%
Cetuximab
11%
Retinoic Acid
10%
Gemcitabine
10%
Colorectal Carcinoma
10%
Antiapoptotic
10%
Prostate Cancer
10%
Protein P53
9%
DNA Topoisomerase (ATP Hydrolysing)
9%
Phosphatidylinositol 3 Kinase
9%
Cancer Growth
9%
Melanoma
9%
Protein Tyrosine Kinase
8%
Mouse Model
8%
Peptide
8%
Remission
8%
Paclitaxel
8%
Vasculotropin
8%
Protein Glutamine Gamma Glutamyltransferase
8%
Messenger RNA
8%
Thioredoxin
7%
Combination Therapy
7%
Cytokine
7%
Cyclin D1
7%
Amphotericin B
7%
IC50
7%
Interferon
7%
Growth Factor
7%
Calcium Ion
7%
STAT3 Protein
7%
Colon Carcinoma
7%
Drug Development
7%
Nucleoside Analog
6%
Multiple Myeloma
6%
Reactive Oxygen Metabolite
6%
Lipid
6%
Gelonin
6%
Caspase
6%
Acute Leukemia
6%
Adenosine Triphosphate
6%
Nanoparticle
6%
Hypoxia Inducible Factor 1
6%
Squamous Cell Carcinoma
6%
Hematologic Malignancy
6%
Thioredoxin Reductase
6%
Phosphotransferase Inhibitor
6%
Lung Cancer
6%
Biological Activity
6%
Nude Mouse
6%
Pharmacodynamics
6%
Tumor Necrosis Factor Receptor
6%
Cyclooxygenase 2
5%
Drug Discovery
5%
Chronic Myeloid Leukemia
5%
Immunotoxin
5%
Western Blot
5%
Clofarabine
5%
Side Effect
5%
Non Small Cell Lung Cancer
5%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
80%
MicroRNA
53%
Programmed Cell Death
52%
Kinase
31%
Phosphotransferase
31%
Carcinogenesis
30%
Tumor Necrosis Factor
28%
phosphorylation
28%
P53
23%
Epidermal Growth Factor Receptor
20%
Signal Transduction
19%
Gene Expression
18%
Tumor Progression
18%
Complement Factor B
18%
Protein Kinase B
17%
Messenger RNA
16%
Cell Proliferation
16%
Transcription Factor
16%
Small Interfering RNA
16%
Downregulation
15%
Cytotoxicity
14%
Promoter Region
14%
Non-Coding RNA
14%
Cell Death
13%
Cell Survival
13%
Enzyme
13%
Cytarabine
13%
Myeloid
13%
Autophagy
12%
Genomics
12%
Drug Resistance
12%
RNA
12%
DNA Gyrase
11%
Upregulation
11%
Long Non-Coding RNA
11%
Cisplatin
11%
Chromosome
11%
Metabolic Pathway
11%
Colon
11%
Cell Cycle
11%
STAT3
11%
Angiogenesis
10%
Cell Growth
10%
Fludarabine
10%
Transcription
10%
Overall Survival
10%
Wild Type
10%
Tumor Suppressor Gene
9%
Adenosine Triphosphate
9%
Peptide
8%
Rat
8%
DNA Damage
8%
Tumor Suppressor Protein
8%
DNA Synthesis
8%
Vascular Endothelial Growth Factor
8%
Tumor Necrosis Factor Receptor
8%
Cyclin D1
8%
Bcl-2
8%
Gemcitabine
8%
Anticancer
8%
Gene Product
7%
CA-125
7%
S Phase
7%
N-Terminus
7%
Fibroblast
7%
Lymphocyte
7%
Nucleotide
7%
Clinical Trial
7%
Phosphoinositide 3-Kinase
7%
DNA Repair
7%
T Cell
7%
Genetics
7%
B Cell
7%
Nucleoside Analog
7%
Receptor Tyrosine Kinase
6%
Protein Kinase
6%
Mouse Model
6%
Protein Expression
6%
extracellular signal regulated kinase
6%
Oncogene
6%
Stem Cell
6%
Cancer Stem Cell
6%
Doxorubicin
6%
Growth Factor
6%
Vidarabine
6%
Methylation
5%
Cell Migration
5%
Epidermal Growth Factor
5%
DNA Strand
5%
Binding Site
5%
Cytokine
5%
Blood Plasma
5%
Chromatin
5%
Mesenchymal-Epithelial Transition
5%
Long Noncoding RNA
5%
Growth Inhibition
5%
Molecular Mechanism
5%
Small Molecule
5%
Expression Level
5%
Monoclonal Antibody
5%